Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis

NCT06015113 is registered in ClinicalTrials.gov with Xi'an International Medical Center Hospital as lead sponsor.

NCT NCT06015113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06015113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
Lead sponsor
Xi'an International Medical Center Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2023
Completion date
April 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer